Tsinghua Holdings

Tsinghua Holdings is a major Chinese state-owned investment group and the primary commercialization vehicle for research originating from Tsinghua University. The company maintains a significant footprint in life sciences and healthcare through major subsidiaries such as Chengzhi Shareholding, Tus-Holdings, and CapitalBio. Its healthcare activities span medical services, pharmaceutical manufacturing, and the development of advanced medical diagnostics, notably holding a dominant global market share in the production of D-ribose. Following a landmark restructuring in 2022, the group was transferred from Tsinghua University to the Sichuan Energy Investment Group, yet it continues to serve as a vital innovation platform bridging academic discovery with industrial application in biotechnology and medical technology.